#pregnancy

The Department of Health and Human Services has updated its HIV treatment and prevention guidelines for pregnant people and their infants.

A 30-year retrospective review of abnormalities among infants born to women using antiretrovirals shows low, consistent levels.

Study results confirm that dolutegravir is a safe and effective treatment for pregnant women with HIV.

But new data add to the evidence that mother-to-infant transmission of the coronavirus appears to be rare.

The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.

PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.

This finding comes from a small focus group of mothers living with HIV in Canada, most of them born in low-income nations.

Among 64 pregnant women who tested positive for SARS-CoV-2, none of their newborns tested positive.

There are many adults today who acquired HIV early in life. Learn about challenges and strength of young female long-term HIV survivors.

On average, it took 37 days for mothers-to-be to clear symptoms of coronavirus infection.

The Well Project asked A Girl Like Me blogger Heather O’Connor about breastfeeding as a woman living with HIV in the United States.

A new UNAIDS report indicates that ambitious targets to prevent and treat HIV in babies and children are not being met.

A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.

For pregnant women with HIV, dolutegravir-based regimens are apparently safest.

The study randomized women starting HIV treatment during their third trimester to dolutegravir- or efavirenz-based antiretroviral regimens.

Updated recommendation includes testing for pregnant women during each pregnancy.